Andrew B. Grossman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew B. Grossman has a total of 551 co-authors. Here are the top co-authors by number of shared publications:
Robert N. Baldassano
2 shared publicationsA. Kim Ritchey
1 shared publication- Aaron Hamvas
Department of Pediatrics, Division of Neonatology, Lurie Children’s Hospital, Northwestern University , Chicago, IL
1 shared publication Abraham Gedalia
1 shared publication- Adam Kirton
Department of Pediatrics University of Calgary Calgary Alberta Canada
1 shared publication Ajit Ashok Sarnaik
1 shared publication
Latest Publications
- 30 July 2020
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 71 (4) , 563-582
Anemia in Children With Inflammatory Bowel Disease
Anemia is one of the most common extraintestinal manifestations of inflammatory bowel disease (IBD). It can be asymptomatic or associated with nonspecific symptoms, such as irritability, headaches, fatigue, dizziness, and anorexia. In IBD patients, the etiology of anemia is often multifactorial. Various causes include iron deficiency, anemia of inflammation and chronic disease, vitamin deficiencies, hemolysis, or myelosuppressive effect of drugs. Anemia and iron deficiency in these patients may be underestimated because of their insidious onset, lack of standardized screening practices, and possibly underappreciation that treatment of anemia is also required when treating IBD. Practitioners may hesitate to use oral preparations because of their intolerance whereas intravenous preparations are underutilized because of fear of adverse events, availability, and cost. Several publications in recent years have documented the safety and comparative efficacy of various intravenous preparations. This article reviews management of anemia in children with IBD, including diagnosis, etiopathogenesis, evaluation of a patient, protocol to screen and monitor patients for early detection and response to therapy, treatment including parenteral iron therapy, and newer approaches in management of anemia of chronic disease. This report has been compiled by a group of pediatric gastroenterologists serving on the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) IBD committee, in collaboration with a pediatric hematologist, pharmacist, and a registered dietician who specializes in pediatric IBD (IBD Anemia Working Group), after an extensive review of the current literature. The purpose of this review is to raise awareness of under‐diagnosis of anemia in children with IBD and make recommendations for screening, testing, and treatment in this population.
- 30 July 2020
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 71 (4) , 563-582
Anemia in Children With Inflammatory Bowel Disease
Anemia is one of the most common extraintestinal manifestations of inflammatory bowel disease (IBD). It can be asymptomatic or associated with nonspecific symptoms, such as irritability, headaches, fatigue, dizziness, and anorexia. In IBD patients, the etiology of anemia is often multifactorial. Various causes include iron deficiency, anemia of inflammation and chronic disease, vitamin deficiencies, hemolysis, or myelosuppressive effect of drugs. Anemia and iron deficiency in these patients may be underestimated because of their insidious onset, lack of standardized screening practices, and possibly underappreciation that treatment of anemia is also required when treating IBD. Practitioners may hesitate to use oral preparations because of their intolerance whereas intravenous preparations are underutilized because of fear of adverse events, availability, and cost. Several publications in recent years have documented the safety and comparative efficacy of various intravenous preparations. This article reviews management of anemia in children with IBD, including diagnosis, etiopathogenesis, evaluation of a patient, protocol to screen and monitor patients for early detection and response to therapy, treatment including parenteral iron therapy, and newer approaches in management of anemia of chronic disease. This report has been compiled by a group of pediatric gastroenterologists serving on the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) IBD committee, in collaboration with a pediatric hematologist, pharmacist, and a registered dietician who specializes in pediatric IBD (IBD Anemia Working Group), after an extensive review of the current literature. The purpose of this review is to raise awareness of under‐diagnosis of anemia in children with IBD and make recommendations for screening, testing, and treatment in this population.
- Open Access
- 12 February 2020
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 4 (1) , 1-7
Establishing the content validity of PROMIS Pediatric pain interference, fatigue, sleep disturbance, and sleep-related impairment measures in children with chronic kidney disease and Crohn’s disease
Background: PROMIS Pediatric patient-reported outcome measures were developed with children from the general population, and their content validity has not been established in children with chronic disease. This study was done to evaluate the content validity of the PROMIS Pediatric Pain Interference and Fatigue measures in children 8–17 years-old with Crohn’s disease and the PROMIS Pediatric Fatigue, Sleep Disturbance, and Sleep-related Impairment measures for children 8–17 years-old with chronic kidney disease. Methods: We conducted semi-structured interviews with individuals affected by Crohn’s disease and chronic kidney disease. The interviews were done to elicit children’s lived experiences of the PROMIS outcomes of interest. We used deductive content analysis to contrast the participants’ reports of their symptoms and impacts on daily life with existing conceptual frameworks for the PROMIS measures, each of which was developed with input from children in the general population. Results: On average, we elicited an average of 7 pain interference and 7 fatigue concepts from Crohn’s disease participants (n = 37), while chronic kidney disease participants (n = 26) provided 9 concepts for fatigue, 4 for sleep disturbance, and 7 for sleep-related impairment. Concept saturation was achieved after 16–19 interviews across the four PROMIS measures. Children with these two chronic health conditions reported the same breadth and types of lived experiences as children from the development samples drawn from the general population. Conclusion: The study supports the content validity of several PROMIS Pediatric measures for children with Crohn’s disease and chronic kidney disease. These findings provide evidence that PROMIS Pediatric measures, developed as universally relevant patient-reported outcomes, may be more broadly applicable to children with chronic disease.
- 12 February 2020
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 4 (1) , 1-7
Open AccessEstablishing the content validity of PROMIS Pediatric pain interference, fatigue, sleep disturbance, and sleep-related impairment measures in children with chronic kidney disease and Crohn’s disease
Background: PROMIS Pediatric patient-reported outcome measures were developed with children from the general population, and their content validity has not been established in children with chronic disease. This study was done to evaluate the content validity of the PROMIS Pediatric Pain Interference and Fatigue measures in children 8–17 years-old with Crohn’s disease and the PROMIS Pediatric Fatigue, Sleep Disturbance, and Sleep-related Impairment measures for children 8–17 years-old with chronic kidney disease. Methods: We conducted semi-structured interviews with individuals affected by Crohn’s disease and chronic kidney disease. The interviews were done to elicit children’s lived experiences of the PROMIS outcomes of interest. We used deductive content analysis to contrast the participants’ reports of their symptoms and impacts on daily life with existing conceptual frameworks for the PROMIS measures, each of which was developed with input from children in the general population. Results: On average, we elicited an average of 7 pain interference and 7 fatigue concepts from Crohn’s disease participants (n = 37), while chronic kidney disease participants (n = 26) provided 9 concepts for fatigue, 4 for sleep disturbance, and 7 for sleep-related impairment. Concept saturation was achieved after 16–19 interviews across the four PROMIS measures. Children with these two chronic health conditions reported the same breadth and types of lived experiences as children from the development samples drawn from the general population. Conclusion: The study supports the content validity of several PROMIS Pediatric measures for children with Crohn’s disease and chronic kidney disease. These findings provide evidence that PROMIS Pediatric measures, developed as universally relevant patient-reported outcomes, may be more broadly applicable to children with chronic disease.
- 1 January 2011
- Published by Elsevier
Contributors
- 1 January 2011
- Published by Elsevier
- p. 1304-1304.e2
Eosinophilic Gastroenteritis
- Open Access
- 1 June 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (6) , 750-755
Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger
Background. 6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) are effective for the induction and maintenance of remission and reduction of corticoster
- 1 June 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (6) , 750-755
Open AccessIncreased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger
Background. 6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) are effective for the induction and maintenance of remission and reduction of corticoster
- 1 February 2008
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 2 (1) , 105-124
Specific considerations in the treatment of pediatric inflammatory bowel disease
Inflammatory bowel disease is one of the most prevalent chronic inflammatory disorders and commonly presents during childhood or adolescence. Occurring during a critical period of growth and development, pediatric Crohn's disease and ulcerative colitis require special consideration. Children often experience growth failure, malnutrition, pubertal delay and bone demineralization. Medical treatment must be optimized to promote clinical improvement and reverse growth failure with minimal toxicity. In addition to pharmacologic and surgical interventions, nutritional therapies play a vital role in the management of pediatric inflammatory bowel disease. This review will outline the epidemiology and clinical complications that are unique to pediatric inflammatory bowel disease, current trends, and recent advances in nutritional and pharmacologic treatment, and projected future therapeutic direction.
- 1 February 2008
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 2 (1) , 105-124
Specific considerations in the treatment of pediatric inflammatory bowel disease
Inflammatory bowel disease is one of the most prevalent chronic inflammatory disorders and commonly presents during childhood or adolescence. Occurring during a critical period of growth and development, pediatric Crohn's disease and ulcerative colitis require special consideration. Children often experience growth failure, malnutrition, pubertal delay and bone demineralization. Medical treatment must be optimized to promote clinical improvement and reverse growth failure with minimal toxicity. In addition to pharmacologic and surgical interventions, nutritional therapies play a vital role in the management of pediatric inflammatory bowel disease. This review will outline the epidemiology and clinical complications that are unique to pediatric inflammatory bowel disease, current trends, and recent advances in nutritional and pharmacologic treatment, and projected future therapeutic direction.